Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) Sees Large Increase in Short Interest

Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) saw a large increase in short interest during the month of February. As of February 28th, there was short interest totalling 1,700 shares, an increase of 88.9% from the February 13th total of 900 shares. Approximately 0.5% of the shares of the company are short sold. Based on an average trading volume of 11,800 shares, the days-to-cover ratio is currently 0.1 days.

Scinai Immunotherapeutics Trading Up 0.5 %

Shares of SCNI stock opened at $3.35 on Friday. The stock has a market capitalization of $2.85 million, a price-to-earnings ratio of -0.01 and a beta of 2.36. The company’s fifty day simple moving average is $3.46 and its two-hundred day simple moving average is $3.48. Scinai Immunotherapeutics has a 1 year low of $2.23 and a 1 year high of $8.92. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.16 and a quick ratio of 1.16.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications.